Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries interim chief legal officer Brian Savage reported equity compensation activity involving restricted share units and ordinary shares. On March 5, 2026, 3,580 restricted share units were converted into 3,580 ordinary shares at a stated price of $0.00 per share, reflecting a vesting event rather than a market purchase. On the same date, he sold 1,127 ordinary shares at a weighted average price of $31.6684 per share, with the shares sold in multiple trades between $31.26 and $32.34. According to the disclosure, these shares were required to be sold to cover tax withholding obligations arising from the vesting of the restricted share units.
Teva Pharmaceutical Industries executive Matthew Shields exercised 17,295 restricted share units into ordinary shares and, on the same day, sold 17,295 ordinary shares in an open-market transaction at a weighted average price of $31.6684. The sale was executed under a Rule 10b5-1 trading plan adopted on November 10, 2025 and included shares sold to cover tax withholding obligations tied to vesting. Following these transactions, Shields directly holds 9,989 ordinary shares and 51,887 restricted share units.
Teva Pharmaceutical Industries President and CEO Richard Francis reported multiple equity transactions on ordinary shares and restricted share units. He exercised 50,223 restricted share units, receiving the same number of ordinary shares at a price of $0.00 per share, as part of a prior equity grant.
On the same date, he received a new award of 136,736 restricted share units, each representing a right to one ordinary share or its cash value at settlement. He then sold 23,393 ordinary shares at a weighted average price of $32.4645 per share, with the shares sold at prices between $32.095 and $33.30 to cover tax withholding obligations under a pre-established Rule 10b5-1 trading plan.
Following these transactions, Francis held 1,148,212 ordinary shares directly.
Teva Pharmaceutical Industries EVP, Europe Commercial Daniell Richard reported a combination of equity awards, vesting and share sales. On March 4, 2026, he exercised restricted share units into 33,512 and 20,461 ordinary shares and received a new grant of 33,424 restricted share units.
He then sold 91,345 ordinary shares in open-market transactions at weighted average prices of $32.4645 and $32.9474, executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following these trades, he directly owned 85,755 ordinary shares. The filing notes the sales related to vesting of restricted share units, including shares sold to cover tax withholding obligations.
Jover Placid reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that officer Jover Placid received a grant of 37,982 restricted share units on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share, or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The award vests in four annual installments, with 9,495 units vesting on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 9,497 units vesting on March 4, 2030. The ordinary shares may be represented by American Depositary Shares, each currently corresponding to one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that EVP, Global Operations Matthew Shields acquired 33,424 restricted share units as a grant on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The award vests in four equal installments of 8,356 units on March 4 of 2027, 2028, 2029, and 2030. The filing notes that the company’s ordinary shares may be represented by American Depositary Shares, and that each ADS currently represents one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD officer Mark Sabag reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised restricted share units into 33,512 ordinary shares and 18,601 ordinary shares at a price of zero per share, increasing his direct holdings. He also received a new grant of 30,385 restricted share units, scheduled to vest in annual installments from March 4, 2027 through March 4, 2030. Each restricted share unit represents a right to one ordinary share or its cash value, and the ordinary shares may be represented by American Depositary Shares.
Lippman Evan reported acquisition or exercise transactions in this Form 4 filing.
Teva Pharmaceutical Industries executive Evan Lippman, EVP of Business Development, received a grant of 27,347 restricted share units (RSUs) on March 4, 2026. Each RSU represents a contingent right to receive either one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share.
The RSUs vest in four annual installments: 6,836 on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 6,839 on March 4, 2030. Following this award, Lippman’s reported derivative holdings from this grant total 27,347 RSUs. The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares, each currently equal to one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Eric A. Hughes reported RSU vesting, a new RSU grant, and a small share sale. On March 4, 2026, he exercised 23,251 restricted share units into the same number of ordinary shares at $0.00 per share and received a new award of 50,643 restricted share units.
He then sold 11,277 ordinary shares at a weighted average price of $32.4645 per share in an open-market transaction effected under a Rule 10b5-1 trading plan, with the footnotes stating this sale was to cover tax withholding from the RSU vesting. After these transactions, he directly held 97,590 ordinary shares and 50,643 restricted share units, each RSU representing a contingent right to one ordinary share or its cash value at settlement.
Teva Pharmaceutical Industries executive vice president and chief financial officer Eliyahu Sharon Kalif reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised previously granted restricted share units into 33,512 ordinary shares and 23,251 ordinary shares at a price of $0.00 per share, reflecting the settlement of vested awards. The filing also shows a new grant of 53,175 restricted share units, each representing a contingent right to receive one ordinary share or its cash value. Following these transactions, his directly owned ordinary shares increased to 305,519. Footnotes describe multi‑year vesting schedules for the 2022, 2024, and 2026 restricted share unit grants, with installments vesting annually through March 4, 2030, and clarify that ordinary shares may be represented by American Depositary Shares on a one‑to‑one basis.